Phase II study of carminomycin in a human tumor cloning assay.
The anticancer activity of carminomycin was investigated in a human tumor cloning assay. No efficacy could be identified in the WiDr and the MCF7 cell lines which were highly responsive to doxorubicin. In addition, drug testing experiments were carried out in samples of various malignancies freshly obtained from 86 patients of whom 54 had not received prior anthracyclines. A reduction in the number of tumor colony forming units by 50% or more was seen in 1/26 breast cancers, 1/22 ovarian cancers and 1/7 melanomas. Cross-resistance studies indicated that eight tumors were responsive to doxorubicin only and one to carminomycin only whereas two were sensitive to both and 73 were resistant to both. This in vitro Phase II study corroborates the disappointing clinical results achieved with carminomycin.
D001943:Breast Neoplasms / Q000188:drug therapy; D002360:Carubicin / Q000494:pharmacology*; D003114:Colony-Forming Units Assay; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000494:pharmacology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D014410:Tumor Stem Cell Assay
D004317:Doxorubicin; D002360:Carubicin; D003630:Daunorubicin